Alacrity Care Raises $500,000 In Private Funding

Alacrity Care’s real-time symptom and vital monitoring sensors allow for continuous tracking of cancer patients’ health status

Los Angeles, CA, January 6 2021—Alacrity Care announced today it has received $500,000 in private funding from a private investor.

These funds will allow Alacrity Care to further develop their product to provide the fastest, safest, and most cost-efficient method of monitoring patients in real time. Their product and platform provides an opportunity for pharmaceutical clinical trials to better monitor the effects of the treatment on patients. With this additional funding, Alacrity Care can expand their product to monitor more vital signs and provide a more accurate real-time picture of patients’ health status.

“This round builds on Alacrity Care’s positive fundraising track record and sets the company up for success in our core initiatives in the first quarter of 2021. We are immensely well-positioned for growth in our target areas and will continue to establish ourselves as the market and thought leaders in the oncologic toxicity management segment,” says COO Avinash Ganesh.

About Alacrity Care

Alacrity Care was founded in 2010 by Dr. David Berz, a leading oncologist with a vision of creating better outcomes for cancer patients in under-served populations and enabling equal access to quality healthcare. Alacrity Care provides patients with equipment that monitor their vitals and allows providers to respond in real time.

CONTACT

For more information, please contact hello@alacritycare.com.

Alacrity Care is located at 2080 Century Park E, Suite 710, Los Angeles, California 90067.